Dupont, M
Clinical trials indicate that participants can lose about 15% of their body weight over 68 weeks
While compounding is strictly limited to the preparation of medicines for individual patients based on a valid prescription, the facility was found to be manufacturing and marketing GIP/GLP-1-based products, including Semaglutide, Tirzepatide, and combination formulations, for broader commercial distribution, particularly for weight management purposes, the two health watchdogs said in a joint statement
Safety and medical history People with complex medical historiesactive gallbladder disease, prior pancreatitis, or specific endocrine concernsshould consult clinicians before starting injectables
less common with sermorelin
Many patients notice reduced appetite and changes in food-related thoughts within the first 14 weeks of treatment, though individual responses vary considerably and gastrointestinal side effects may be prominent initially